Lung cancer cells may develop resistance after receiving combination therapy.

Published Date: 17 Apr 2024

In certain patients, a particular genetic change called an ALK fusion is the cause of non-small cell lung cancer. The ALK protein, a major cancer promoter, becomes overactive as a result of this anomaly. It's possible to treat these tumors.

Read Full News

Latest News

WHO Flags Growing Health Workforce Gap as Workers and Patients Age

The World Health Organization warned on Friday of a gap ⁠in the medical workforce around the world in the 2030s, with a quarter ⁠of doctors set to retire in the next...

Doctors Are Leaning Into Anti-Hustle Vacations

Some doctors are trading crammed itineraries for something radical on vacation: doing absolutely nothing at all.

The Market Forces Quietly Adding Thousands to Patient Bills

Over the past decade, the number of doctors working for hospitals rather than in private practice has more than doubled.

FDA Clears First Standalone Robotic Blood Draw System

A new robotic system is drawing blood in adult patients, but its real-world impact may depend on how often it skips difficult veins.

Med Students’ Secret Weapon? Sleep

Rather than cramming for med school exams all night with little sleep, med students should know that sleep is the key to better learning and memorizing new information.

Oncology Firm Novocure Says Cyberattack Exposed US Patient Records

Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized ⁠access to certain information systems in mid-August exposed internal records of...

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

The World Health Organization warned on Friday of a gap ⁠in the medical workforce around the world in the 2030s, with a quarter ⁠of doctors set to retire in the next...

Some doctors are trading crammed itineraries for something radical on vacation: doing absolutely nothing at all.
HTTP error: 503HTTP error: 503

Rather than cramming for med school exams all night with little sleep, med students should know that sleep is the key to better learning and memorizing new information.
HTTP error: 503

News All Time

HTTP error: 503HTTP error: 503HTTP error: 503

Cigna Invests $100 Million in New AI-powered Specialty Pharmacy Program

Cigna said on Wednesday its health services unit Evernorth has launched a new ⁠AI-powered specialty pharmacy program to reduce the time it takes to process prescriptions and...

Resident Doctors in England Vote for UK Government's Pay Offer, Ending Strikes

Resident doctors in England have voted to accept the government's latest pay and job offer, their ⁠union said on Monday, bringing an end to a long-running industrial dispute...

Democratic-led States Sue Over Trump Administration's Medicaid Work Requirement Rule

A coalition of Democratic-led states sued on Monday to block a Trump administration rule implementing new work requirements for Medicaid recipients, ⁠arguing it unlawfully...
HTTP error: 503HTTP error: 503

Medicare AI Creates Errors and Delays for Patients, Doctors

Patients, doctors, and other healthcare professionals who spoke with KFF Health News say the effort has created confusion, errors, long wait times, and stress.
HTTP error: 503

Studies Confirm Private Equity Dangers

A handful of studies confirm that hospitals taken over by private equity have worse outcomes for patients.
HTTP error: 503

Nurses Filling Doctor Gaps: What Happens to Hard Cases?

As health systems consider shifting more physician tasks to nurses, Medscape readers focused on whether expanded care models include clear supervision, escalation, and time for patients who do not fit routine protocols.

FDA Grants Emergency Approval for Over-the-counter Drug to Treat Screwworm in Pets

The U.S. Food and Drug Administration on Thursday authorized the emergency use of a generic over-the-counter tablet ⁠to treat infestations caused by the New World screwworm...

More Nurses are Clocking in to Second Jobs

More nurses regularly take on second shifts but as the practice becomes normalized, is this best for patients?

Sandoz Files European Complaint About Chinese Antibiotic Imports

Swiss generic drugmaker Sandoz filed a draft ⁠anti-dumping complaint with the European Commission over Chinese imports ⁠of the antibiotic ingredient amoxicillin.

Recommended News For You

What are the factors that cause oral mucositis to be severe after receiving radiation for head and neck cancer?

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.

Hemihedral resection not necessary for neuroendocrine surgery after appendicitis

One possible target in acute myeloid leukemia is the reductive carboxylation of glutamine.

Recommended Articles For You

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis 

Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer 

Iron Metabolism and Inflammatory Disorders: Mechanisms, Clinical Implications, and Therapeutic Approaches 

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?

2.

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

3.

Biomarker panel offers hope for early pancreatic cancer detection

4.

Financial hardship common in patients with cancer

5.

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

1.

What You Need To Know About Secondary Polycythemia: Treatment & Symptoms

2.

Emerging Methods in Hematology in Clinical Decision-Making

3.

Fatigue Rehabilitation in Blood Disorders

4.

Digital Morphology Libraries for Hematology Education: Transforming Diagnostic Training and Clinical Practice

5.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

2.

Early Cancer Detection Saves Lives

3.

The Role of Hemoglobin in Maintaining Healthy Oxygen Levels

4.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

5.

A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot